Dubroff: Markets face crosswinds but dollar resigns in New Year
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our view: Region’s economy has a lot to answer in 2024
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind looks to clear up debt with capital from royalty agreement
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Region’s top stocks look to dominate their industries
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Generative AI will take off in 2024, area experts say
2024 will be the year of the new wave of artificial intelligence — generative AI — Tri-County experts in the field say. Most, if not all, AI companies and other businesses that use AI will be dialing into the cutting-edge technology more and more, the specialists say. They include those in the Central Coast region Read More →
MannKind inks royalty purchase agreement for up to $200M
Westlake Village-based MannKind Corporation saw shares climb 8% on Jan. 2 after the company announced entering into a royalty purchase agreement of up to $200 million. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, sold a 1% royalty in net sales of Tyvaso DPI to Sagard Healthcare on Dec. 27. Read More →
